Case Details
- Citation: [2022] SGHC(A) 21
- Title: Yong Khong Yoong Mark & 2 Ors v Ting Choon Meng & Anor
- Court: Appellate Division of the High Court of the Republic of Singapore
- Date: 18 May 2022
- Case Number: Civil Appeal No 121 of 2021
- Related Suit: Suit No 1140 of 2018
- Judges: Belinda Ang Saw Ean JAD, Woo Bih Li JAD and Hoo Sheau Peng J
- Appellants/Plaintiffs: (1) Yong Khong Yoong Mark; (2) Emily Hwang Mei Chen; (3) Medivice Investment Limited
- Respondents/Defendants: (1) Ting Choon Meng; (2) Chua Ngak Hwee
- Legal Areas: Contract; Misrepresentation; Tort of misrepresentation (fraudulent/negligent/inducement); Unlawful means conspiracy
- Statutes Referenced: Not specified in the provided extract
- Prior Decision: Yong Khong Yoong Mark and others v Ting Choon Meng and another [2021] SGHC 246
- Cases Cited: [2021] SGHC 246
- Judgment Length: 16 pages, 4,204 words
Summary
Yong Khong Yoong Mark & 2 Ors v Ting Choon Meng & Anor concerned claims in misrepresentation and unlawful means conspiracy arising from a series of investments into HealthSTATS International Pte Ltd (“Healthstats International”). The appellants alleged that the respondents made representations—some fraudulent or negligent—about regulatory approvals, revenue bookings, and product launch plans. These representations, the appellants contended, induced them to advance loans totalling about $2.5m between January and July 2016 and to enter a $5m subscription agreement in August 2016.
The Appellate Division dismissed the appeal. While the High Court judge had found that at least one aspect of the regulatory representation (relating to the BPro G2 and the US FDA) was falsely made, the appellate court held that the appellants failed to prove a crucial element: that the representations were in play at the time the subscription agreement was entered. The court also accepted that certain statements were not actionable because they were statements of future intention. Most importantly, the appellants did not establish that the representations played a real and substantial role in inducing the relevant transactions.
What Were the Facts of This Case?
The dispute arose from the appellants’ investment strategy involving Healthstats International, a company associated with medical devices and related products, including the BPro G2, BPro G3, and CasPro devices. The appellants’ pleaded case was that, between September 2015 and February 2016, the respondents made representations about the regulatory status of the company’s products, its revenue bookings, and its planned product launch timeline. The appellants claimed that these representations induced them to make loans and later to subscribe for shares under a subscription agreement.
In broad terms, the appellants alleged three categories of representations. First, the “Regulatory Representation” was that Healthstats International’s products—particularly the BPro G2 and CasPro devices—had obtained necessary regulatory approvals from Singapore’s Health Sciences Authority, the US Food and Drug Administration (“FDA”), and the European Union’s Conformité Européenne (“CE”). Second, the “Revenue Representation” was that $18m of sales had been booked for 2016 and $38.2m for 2017. Third, the “Product Representation” was that Healthstats International would launch the BPro G3 in the second quarter of 2016.
After the alleged representations were made, significant events occurred before the August 2016 subscription agreement. On 2 December 2015, Mr Yong executed a letter of intent on behalf of his investment vehicle, Uncharted Holdings Limited (“Uncharted”), indicating an intention to purchase shares in Healthstats International for about $27m. By that time, Healthstats International had entered a joint venture arrangement with Winsan (Shanghai) Medical Science and Technology Co Ltd (“Winsan”) through HealthSTATS Technology (SIP) Co Ltd (“Healthstats China”). Under the China Contracts, Healthstats China was to purchase specified quantities and values of BPro G2 devices and accessories, and also BPro G2, BPro G3, and CasPro devices and accessories.
From 8 January 2016 to 8 April 2016, Uncharted commissioned extensive due diligence. The due diligence involved multiple professional advisers, including DLA Piper UK LLP, KPMG Services Pte Ltd, and Baker & McKenzie, Wong & Leow. Mr Yong also approached a Shanghai-based law firm partner, Mr John Sheng, to look into Winsan and Healthstats China on his behalf. Following the due diligence, Uncharted decided not to proceed with the $27m investment. In its initial notice of termination dated 25 April 2016, Uncharted stated that due diligence had not been completed to its satisfaction. Later, in an email dated 26 April 2016, Mr Yong clarified to Dr Ting that Uncharted’s main concerns related to Winsan’s financial soundness and issues concerning Winsan and Healthstats China. Mr Yong even recommended that Dr Ting consider a full independent audit of Healthstats China.
Crucially, the court emphasised that Mr Yong’s concerns were not limited to regulatory matters. He indicated he was not comfortable with Healthstats China and doubted the feasibility of the China Contracts’ commitments. At the same time, Mr Yong informed Dr Ting that Uncharted had commissioned due diligence on Healthstats International, its patents, and Healthstats China. The appellate court treated this as evidence that Mr Yong’s intention was to verify the accuracy of the representations. Save for concerns relating to Healthstats China and Winsan, Mr Yong clarified that Uncharted was “fine” with the results of due diligence on Healthstats International and the patents, and that Uncharted still “loved” the products and remained interested in investing, albeit not at the then valuation.
Another important factual thread was the role of Mr Joshua Soh as Chief Executive Officer of Healthstats International. Mr Yong had brought Mr Soh in with the primary role of changing the sales-based model to a service-based model from March 2016. The service-based model for the BPro G2 involved giving devices to clinical professionals for free, charging per use instead of selling devices. Dr Ting testified that Mr Yong had explained that the service-based model in the US would be more lucrative than the Second China Contract. Even after Uncharted withdrew from the $27m investment, Mr Soh continued as Mr Yong’s nominee in Healthstats International until April 2017.
Finally, the appellants’ loans and the subscription agreement were connected but not identical. The appellants had already extended substantial loans to Healthstats International by the time of the August 2016 subscription agreement. The court accepted that these loans were made for working capital purposes while Mr Yong was considering whether to invest. The loans were later offset against the $5m due under the subscription agreement. This meant that the appellants’ decision to enter the subscription agreement could not be analysed in isolation from the earlier loans and the intervening due diligence and concerns.
What Were the Key Legal Issues?
The appeal required the Appellate Division to consider whether the appellants could establish actionable misrepresentation and, if so, whether the misrepresentations were causally linked to the transactions. Although the parties did not dispute the general law on misrepresentation, the appellate court focused on the application of those principles to the evidence.
One key issue was whether the representations were continuing at the time the subscription agreement was entered in August 2016. The appellants pleaded that representations made between September 2015 and February 2016 induced them to enter the subscription agreement in August 2016. The burden lay on the appellants to show that the representations remained in play at the relevant time. This required proof not merely that representations were made earlier, but that they were still operative in influencing the decision to contract.
Another issue concerned whether certain statements were actionable. The High Court had characterised the revenue and product statements as statements of future intention rather than present facts. The appellate court had to assess whether those statements could ground a misrepresentation claim and whether, in any event, they were causally connected to the subscription agreement.
Finally, the appeal also involved tort claims, including fraudulent and negligent misrepresentation, and unlawful means conspiracy. However, the appellate court’s reasoning indicates that the causation and “in play” elements were decisive, such that even if some representations were false, the appellants could not succeed without proving that the representations materially induced the relevant transactions.
How Did the Court Analyse the Issues?
The Appellate Division approached the case by focusing on the evidential narrative between the alleged misrepresentations and the August 2016 subscription agreement. The court noted that the appellants’ pleaded case depended on showing that the representations were continuing at the time of contracting. It was therefore “crucial” to examine what happened after the representations were made and before the subscription agreement was signed.
In the court’s view, the evidence demonstrated that the representations were not in play when the appellants entered into the subscription agreement. The court treated Uncharted’s due diligence and subsequent withdrawal as a turning point. The extensive due diligence process, involving multiple reputable firms, suggested that the appellants were actively verifying information rather than relying solely on the respondents’ earlier statements. More importantly, Mr Yong’s own communications after due diligence showed that his concerns had shifted to issues about Winsan’s financial status and the feasibility of the China Contracts—matters that were not the same as the alleged misrepresentations about regulatory approvals, revenue bookings, or product launch timing.
The court also relied heavily on Mr Yong’s evidence. The appellants asserted that the representations induced them to enter the subscription agreement. However, the appellate court found that Mr Yong’s affidavit evidence-in-chief contradicted that assertion. Instead, Mr Yong explained that after he became aware of concerns about Winsan in February 2016 and doubted the feasibility of the China Contracts, he still considered making a small private investment. The purpose, as described by Mr Yong, was to put Healthstats International in a position to meet production obligations under the First China Contract, which would “create momentum” and increase the chances of the Second China Contract being performed.
This explanation was consistent with other evidence, including Dr Ting’s testimony about the potential of the service-based model. The appellate court considered that Mr Yong’s decision-making was driven by a combination of factors: his continued interest in Healthstats International’s products, his belief that the service-based model could improve profitability and enable market penetration (including in the US), and the fact that substantial portions of the investment could be offset against earlier loans. The court therefore concluded that even if the representations were false, the appellants had not shown that the representations played a real and substantial role in inducing the subscription agreement.
On the regulatory representation, the High Court had found that the BPro G2 FDA approval statement was falsely made. The appellate court did not treat this as sufficient for liability. The decisive point remained whether the appellants could establish that the regulatory misstatement was causally connected to the August 2016 subscription decision. The court’s analysis suggests that the appellants’ decision was not anchored to the regulatory status as represented, but rather to later developments and to their own assessment of feasibility and business strategy.
Regarding the revenue and product representations, the High Court had held that these were statements of future intention and therefore not actionable representations. While the appellate extract does not elaborate on the full reasoning for this characterisation, the appellate court accepted the High Court’s approach. This reinforces an important doctrinal point in misrepresentation law: statements about future performance, plans, or intentions generally require careful scrutiny to determine whether they amount to present facts (such as existing commitments or knowledge) or are merely predictions and intentions.
Overall, the appellate court’s reasoning reflects a causation-focused approach. Misrepresentation claims require proof of inducement: the misrepresentation must have played a real and substantial role in the claimant’s decision to enter the contract or make the relevant transaction. By emphasising the “in play” requirement and by scrutinising the appellants’ own evidence of their decision-making, the court effectively applied a rigorous evidential standard to the causation element.
What Was the Outcome?
The Appellate Division dismissed AD/CA 121 and upheld the High Court judge’s dismissal of the appellants’ claims in misrepresentation and unlawful means conspiracy. The practical effect was that the appellants did not obtain any relief against Dr Ting and Mr Chua arising from the alleged misrepresentations.
In doing so, the court confirmed that even where a representation is found to be false (such as the BPro G2 FDA approval statement), a claimant must still prove that the representation was continuing at the time of contracting and that it materially induced the transaction. The appellants’ inability to establish these elements was fatal to the claims.
Why Does This Case Matter?
This decision is significant for practitioners because it illustrates how Singapore courts evaluate misrepresentation claims through the lens of causation and temporal relevance. The “continuing representations” concept is especially important where representations are made months before the contract is signed. Claimants must show not only that representations were made and were false, but also that they remained operative in influencing the claimant’s decision at the time of contracting.
The case also demonstrates the evidential weight courts place on contemporaneous due diligence and on the claimant’s own explanations of decision-making. Where the claimant undertakes extensive due diligence, receives information that shifts concerns to other issues, and later articulates reasons for contracting that do not align with the pleaded misrepresentations, courts may find that inducement is not established. For defendants, this provides a roadmap to challenge misrepresentation claims by focusing on the claimant’s decision trail rather than only on the falsity of statements.
From a doctrinal perspective, the decision reinforces that statements of future intention or predictions about revenue and product launches may not be actionable as misrepresentations unless they can be shown to contain present factual assertions or actionable commitments. For law students and litigators, the case is a useful example of how courts separate actionable misstatements from non-actionable forward-looking statements and then apply the inducement requirement to determine liability.
Legislation Referenced
- Not specified in the provided extract.
Cases Cited
- Yong Khong Yoong Mark and others v Ting Choon Meng and another [2021] SGHC 246
Source Documents
This article analyses [2022] SGHCA 21 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.